SCHEMBL2835283

SCHEMBL2835283

Cc1ccc(C(N)C#N)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.45
SLC6A3 Q01959 2/20 0.37
USP2 O75604 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CD44 P16070 1/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ATM Q13315 1/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836720 0.87 S1PR1 (0.38) CYP3A4SLC6A3CD44KMT2AALDH1A1
SCHEMBL6991220 0.84 SLC6A3 (0.50) CYP3A4SLC6A3
Hydrochloric Acid SCHEMBL5685365 0.82 SLC6A3 (0.49) CYP3A4SLC6A3
SCHEMBL11664750 0.79 CA1 (0.44) SLC6A3HSD17B10MAPTKMT2ARECQL
SCHEMBL8286723 0.78 ADRB2 (0.52) CYP3A4SLC6A3CD44MAPTKMT2A
SCHEMBL8284220 0.77 CYP3A4 (0.45) CYP3A4CD44MAPTKMT2AHTR3E
SCHEMBL10988468 0.77 ESR1 (0.39) CYP3A4SLC6A3USP2HSD17B10L3MBTL1
Hydrochloric Acid SCHEMBL4936460 0.76 ADRB2 (0.50) CYP3A4SLC6A3CD44MAPTKMT2A
Hydrochloric Acid SCHEMBL4931415 0.76 CYP3A4 (0.44) CYP3A4SLC6A3CD44MAPTKMT2A
SCHEMBL2834867 0.76 RPS6KB1 (0.40) SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
CN-102333569-A Amine or amino alcohols as glyt1 inhibitors HOFFMANN LA ROCHE 2012-01-25 CN disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 CYP3A4 1043/4885SLC6A3 12/4885USP2 4556/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 CYP3A4 1043/4885SLC6A3 12/4885USP2 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.